BridgeBio Oncology Therapeutics, Inc. (BBOT NASDAQ) stock market data APIs
$12.061
-0.31(-2.6%)
as of February 2, 2026
Try our APIs with
free plan!
BridgeBio Oncology Therapeutics, Inc. Financial Data Overview
Price chart is built with
Anychart
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics targeting renin-angiotensin system and phosphoinositide 3-kinase malignancies. The company's product pipeline includes BBO-8520, a direct inhibitor targeting the on and off states of KRAS that is in Phase I clinical trial to treat patients with KRASG12C mutant non-small cell lung cancer; and BBO-10203, an orally bioavailable small molecule that is in Phase I clinical trial for treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS pancreatic ductal adenocarcinoma (PDAC), KRAS mutant colorectal cancer (CRC), and KRAS mutant NSCLC. It is also developing BBO-11818, an orally bioavailable pan KRAS on/off inhibitor that is in Phase I clinical trial to treat patients with KRASG12D and KRASG12V mutant NSCLC, PDAC, and CRC. The company was founded in 2016 is headquartered in South San Francisco, California.
Prev. Close
12.061
Open
11.7558
High
12.3834
Low
11.7329
52 wk Range
8.7-14.87
Market Cap
1 005 M
Shares Outstanding
79 197 K
EPS
-1.03
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with BridgeBio Oncology Therapeutics, Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get BridgeBio Oncology Therapeutics, Inc. data using free add-ons & libraries
Get BridgeBio Oncology Therapeutics, Inc. Fundamental Data
BridgeBio Oncology Therapeutics, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -94 546 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-12
- EPS/Forecast: -0.34
Get BridgeBio Oncology Therapeutics, Inc. End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
BridgeBio Oncology Therapeutics, Inc. News
New
BridgeBio Oncology gains outperform rating from Raymond James
[Wall Street sign in Lower Manhattan, NYC] georgeclerk * Raymond James initiated BridgeBio Oncology Therapeutics (BBOT [https://seekingalpha.com/symbol/BBOT]) at outperform, noting the company is w...
BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs
BBO-8520 monotherapy in patients with KRASG12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month progression-free survival (PFS), with 83% of patients el...
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?
Key Points Cormorant Asset Management added 251,600 shares in Rapport Therapeutics; the reported position value increased by approximately $61.38 million over the prior quarter. The change represents...
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?
Key Points Cormorant Asset Management added 251,600 shares in Rapport Therapeutics; the reported position value increased by approximately $61.38 million over the prior quarter. The change represents...
Get BridgeBio Oncology Therapeutics, Inc. fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
